Intellia Therapeutics faced significant challenges in Q3 2025, including a clinical hold on its nex-z program following serious safety concerns, while making substantial progress in its lonvo-z development for hereditary angioedema.

• The FDA imposed a clinical hold on both the MAGNITUDE and MAGNITUDE-2 trials of nex-z due to safety issues, including increased liver enzyme levels in a patient who later passed away.
• Enrollment for the Phase III trial of lonvo-z was completed ahead of schedule, with top-line data expected by mid-2026 and a potential U.S. launch in early 2027.
• Intellia's cash position remains strong at $669.9 million, bolstered by a $115 million capital raise, extending its cash runway into mid-2027.
• Collaboration revenue climbed to $13.8 million, primarily due to cost reimbursements from Regeneron Pharmaceuticals, reflecting active partnerships.
• R&D expenses decreased to $94.7 million, driven by cost-cutting measures, highlighting the company's focus on managing operational expenditures amidst program uncertainties.